Literature DB >> 35102278

Bioengineering strategies for restoring vision.

Jasmina Cehajic-Kapetanovic1,2, Mandeep S Singh3, Eberhart Zrenner4, Robert E MacLaren5,6.   

Abstract

Late-stage retinal degenerative disease involving photoreceptor loss can be treated by optogenetic therapy, cell transplantation and retinal prostheses. These approaches aim to restore light sensitivity to the retina as well as visual perception by integrating neuronal responses for transmission to the cortex. In age-related macular degeneration, some cell-based therapies also aim to restore photoreceptor-supporting tissue to prevent complete photoreceptor loss. In the earlier stages of degeneration, gene-replacement therapy could attenuate retinal-disease progression and reverse loss of function. And gene-editing strategies aim to correct the underlying genetic defects. In this Review, we highlight the most promising gene therapies, cell therapies and retinal prostheses for the treatment of retinal disease, discuss the benefits and drawbacks of each treatment strategy and the factors influencing whether functional tissue is reconstructed and repaired or replaced with an electronic device, and summarize upcoming technologies for enhancing the restoration of vision.
© 2022. Springer Nature Limited.

Entities:  

Year:  2022        PMID: 35102278     DOI: 10.1038/s41551-021-00836-4

Source DB:  PubMed          Journal:  Nat Biomed Eng        ISSN: 2157-846X            Impact factor:   25.671


  186 in total

1.  Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial.

Authors:  Stephen Russell; Jean Bennett; Jennifer A Wellman; Daniel C Chung; Zi-Fan Yu; Amy Tillman; Janet Wittes; Julie Pappas; Okan Elci; Sarah McCague; Dominique Cross; Kathleen A Marshall; Jean Walshire; Taylor L Kehoe; Hannah Reichert; Maria Davis; Leslie Raffini; Lindsey A George; F Parker Hudson; Laura Dingfield; Xiaosong Zhu; Julia A Haller; Elliott H Sohn; Vinit B Mahajan; Wanda Pfeifer; Michelle Weckmann; Chris Johnson; Dina Gewaily; Arlene Drack; Edwin Stone; Katie Wachtel; Francesca Simonelli; Bart P Leroy; J Fraser Wright; Katherine A High; Albert M Maguire
Journal:  Lancet       Date:  2017-07-14       Impact factor: 79.321

2.  Retinal AAV8-RS1 Gene Therapy for X-Linked Retinoschisis: Initial Findings from a Phase I/IIa Trial by Intravitreal Delivery.

Authors:  Catherine Cukras; Henry E Wiley; Brett G Jeffrey; H Nida Sen; Amy Turriff; Yong Zeng; Camasamudram Vijayasarathy; Dario Marangoni; Lucia Ziccardi; Sten Kjellstrom; Tae Kwon Park; Suja Hiriyanna; J Fraser Wright; Peter Colosi; Zhijian Wu; Ronald A Bush; Lisa L Wei; Paul A Sieving
Journal:  Mol Ther       Date:  2018-07-07       Impact factor: 11.454

3.  Prevalence of mutations causing retinitis pigmentosa and other inherited retinopathies.

Authors:  M M Sohocki; S P Daiger; S J Bowne; J A Rodriquez; H Northrup; J R Heckenlively; D G Birch; H Mintz-Hittner; R S Ruiz; R A Lewis; D A Saperstein; L S Sullivan
Journal:  Hum Mutat       Date:  2001       Impact factor: 4.878

Review 4.  Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis.

Authors:  Wan Ling Wong; Xinyi Su; Xiang Li; Chui Ming G Cheung; Ronald Klein; Ching-Yu Cheng; Tien Yin Wong
Journal:  Lancet Glob Health       Date:  2014-01-03       Impact factor: 26.763

5.  Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10.

Authors:  Morgan L Maeder; Michael Stefanidakis; Christopher J Wilson; Reshica Baral; Luis Alberto Barrera; George S Bounoutas; David Bumcrot; Hoson Chao; Dawn M Ciulla; Jennifer A DaSilva; Abhishek Dass; Vidya Dhanapal; Tim J Fennell; Ari E Friedland; Georgia Giannoukos; Sebastian W Gloskowski; Alexandra Glucksmann; Gregory M Gotta; Hariharan Jayaram; Scott J Haskett; Bei Hopkins; Joy E Horng; Shivangi Joshi; Eugenio Marco; Rina Mepani; Deepak Reyon; Terence Ta; Diana G Tabbaa; Steven J Samuelsson; Shen Shen; Maxwell N Skor; Pam Stetkiewicz; Tongyao Wang; Clifford Yudkoff; Vic E Myer; Charles F Albright; Haiyan Jiang
Journal:  Nat Med       Date:  2019-01-21       Impact factor: 53.440

6.  Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremia.

Authors:  Kanmin Xue; Jasleen K Jolly; Alun R Barnard; Anna Rudenko; Anna P Salvetti; Maria I Patrício; Thomas L Edwards; Markus Groppe; Harry O Orlans; Tanya Tolmachova; Graeme C Black; Andrew R Webster; Andrew J Lotery; Graham E Holder; Susan M Downes; Miguel C Seabra; Robert E MacLaren
Journal:  Nat Med       Date:  2018-10-08       Impact factor: 53.440

7.  CRISPR genome engineering for retinal diseases.

Authors:  Ariel Kantor; Michelle E McClements; Caroline F Peddle; Lewis E Fry; Ahmed Salman; Jasmina Cehajic-Kapetanovic; Kanmin Xue; Robert E MacLaren
Journal:  Prog Mol Biol Transl Sci       Date:  2021-03-19       Impact factor: 3.622

8.  A comparison of the causes of blindness certifications in England and Wales in working age adults (16-64 years), 1999-2000 with 2009-2010.

Authors:  Gerald Liew; Michel Michaelides; Catey Bunce
Journal:  BMJ Open       Date:  2014-02-12       Impact factor: 2.692

9.  Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR.

Authors:  Jasmina Cehajic-Kapetanovic; Kanmin Xue; Cristina Martinez-Fernandez de la Camara; Anika Nanda; Alexandra Davies; Laura J Wood; Anna Paola Salvetti; M Dominik Fischer; James W Aylward; Alun R Barnard; Jasleen K Jolly; Edmond Luo; Brandon J Lujan; Tuyen Ong; Aniz Girach; Graeme C M Black; Ninel Z Gregori; Janet L Davis; Potyra R Rosa; Andrew J Lotery; Byron L Lam; Paulo E Stanga; Robert E MacLaren
Journal:  Nat Med       Date:  2020-02-24       Impact factor: 53.440

Review 10.  Genome-Editing Strategies for Treating Human Retinal Degenerations.

Authors:  Joel Quinn; Ayesha Musa; Ariel Kantor; Michelle E McClements; Jasmina Cehajic-Kapetanovic; Robert E MacLaren; Kanmin Xue
Journal:  Hum Gene Ther       Date:  2020-11-19       Impact factor: 5.695

View more
  1 in total

1.  N-acylethanolamide metabolizing enzymes are upregulated in human neural progenitor-derived neurons exposed to sub-lethal oxidative stress.

Authors:  R Scott Duncan; Sean M Riordan; Conner W Hall; Andrew J Payne; Kent D Chapman; Peter Koulen
Journal:  Front Cell Neurosci       Date:  2022-08-08       Impact factor: 6.147

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.